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ABSTRACT: The impact of melt extrusion (HME) and spray drying (SD) on mechanical properties of hypromellose acetate succinate
(HPMCAS), copovidone, and their formulated blends was studied and compared with that of reference excipients. Tensile strength (TS),
compression pressure (CP), elastic modulus (E), and dynamic hardness (Hd) were determined along with Hiestand indices using compacts
prepared at a solid fraction of ∼0.85. HPMCAS and copovidone exhibited lower Hd, lower CP, and lower E than the reference excipients
and moderate TS. HPMCAS was found to be highly brittle based on brittle fracture index values. The CP was 24% and 61% higher for
HPMCAS after SD and HME, respectively, than for unprocessed material along with a higher Hd. Furthermore, the TS of HPMCAS and
copovidone decreased upon HME. Upon blending melt-extruded HPMCAS with plastic materials such as microcrystalline cellulose, the
TS increased. These results suggest that SD and HME could impact reworkability by reducing deformation of materials and in case of HME,
likely by increasing density due to heating and shear stress in a screw extruder. A somewhat similar effect was observed for the dynamic
binding index (BId) of the excipients and formulated blends. Such data can be used to quantitate the impact of processing on mechanical
properties of materials during tablet formulation development. C© 2013 Wiley Periodicals, Inc. and the American Pharmacists Association
J Pharm Sci 102:3604–3613, 2013
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INTRODUCTION AND BACKGROUND
The design and development of solid dosage forms and galeni-
cal processes rely on both the physicochemical and mechani-
cal properties of the active ingredient, excipient components,
and the mixtures thereof. Certainly, physical properties are
closely linked to final product specifications such as purity,
uniformity, dissolution, stability, appearance, and mechanical
durability.1 While physical properties clearly influence powder
flow and compression, the mechanical properties of materials,
those properties of a material subject to an applied stress, are
of great importance in solid dosage form development and man-
ufacturing. The impact of such properties on material behavior
during galenical processing has been demonstrated by instru-
mented tablet press, compression simulator, and mechanical
testing devices.2–4
Based on the characteristics of the drug substance, excipi-
ents that complement or compensate for drug properties may be
chosen along with processing equipments to favorably improve
the behavior of materials under stress conditions. These evalu-
ations are tied to FDA’s new risk-based pharmaceutical quality
assessment system in developing pharmaceutical cGMPs for
the 21st century, where achieving and maintaining a state of
control for a process is considered as beginning at the formula-
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tion and process development phase and continuing through-
out the commercial phase of a product’s life cycle. This new
assessment system focuses on pharmaceutical critical quality
attributes such as pharmaceutical raw material properties as
well as formulation and manufacturing processes as they relate
to product performance.5–7 While there are some generalized
procedures to evaluate material properties of active pharma-
ceutical ingredient (API), excipients, and mixtures, the impact
of a given material (API or excipient) is dependent on its con-
centration in the formulation, its function, as well as any as-
sociated processing, and therefore needs to be studied in the
context of its ability to affect the performance of a formulation
or process.
The value of proper compaction characterization, i.e. assess-
ment of the tensile strength (TS)—compression pressure (CP)—
solid fraction (SF) relationships leading to the compactability,
tabletability, and compressibility (CTC) profiles, provides ba-
sic mechanical property information and has been discussed
previously.8 Along with TS, CP, and SF, the elastic modulus,
permanent deformation pressure, and brittleness of compacts
are additional important properties used to quantify the me-
chanical nature of materials. These properties, therefore, are of
significant interest in supporting tablet development in a sci-
entific manner. To characterize and compare these properties
of materials with different deformation behavior, experimental
methods and dimensionless tableting indices (DTI) were de-
veloped by Hiestand and Smith.9,10 The tableting indices are
dimensionless numbers that profile the regions of interparticle
3604 Iyer et al., JOURNAL OF PHARMACEUTICAL SCIENCES 102:3604–3613, 2013
RESEARCH ARTICLE – Pharmaceutics, Drug Delivery and Pharmaceutical Technology 3605
contact, the so-called “isthmus” regions between contacting par-
ticles. It is at these regions where plastic deformation and the
generation of large areas of true contact during decompres-
sion are necessary to produce significant tablet strength. The
DTI, in combination with compaction characterization, yield a
more complete assessment of the multidimensional nature of
mechanical properties of materials. The bonding index (BI), for
example, is a measure of the extent of plastic deformation or
material strength that remains after decompression and recov-
ery of a compact. It is thus a measure of bonding efficiency.
A brittleness index called the brittle fracture index (BFI), de-
rived from TS measurements, is a measure of brittleness (frac-
turing tendency) of compacted material. High BFI values are
typically seen with brittle materials that undergo fragmenta-
tion. The third index called strain index (SI) indicates roughly
the relative strain energy that could develop at a “crack” or
other stressed region of the compact during elastic recovery af-
ter plastic deformation has occurred. This index combines the
elastic and plastic deformation properties of a material and is
a measure of the internal entropy or strain in a material when
compacted. Finally, a fourth index termed the viscoelasticity
index (VI) has been found to be useful as a measure of viscous
(time dependent, irreversible) and elastic (reversible) deforma-
tion in a compact.4
Since the tablet is the most prevalent dosage form that
utilizes powder compression, the DTI developed by Hiestand
has been used to characterize the behavior of materials dur-
ing tableting.11–13 Statistical approaches using factorial de-
signs have been employed to identify experimental conditions
that can differentiate materials based on the tableting indices.
These have included indenter specifications, compact size, and
storage time, but the type of material (deformation behavior)
has been the primary determinant of differentiation.14 The
application of DTI to characterize powder compaction behav-
ior by various methods has shown mixed results. The indices
have been compared with that of Luenberger’s percolation the-
ory using different excipients with brittle or plastic charac-
teristics. The comparison showed the two approaches to be
complementary15 especially for plastically deforming excipients
whereby the BI was found to increase with the characteristic
relative density, D*r, of such excipients. In empirical evalu-
ations, the DTI were correlated with the impact of material
properties on processing behavior such as granulation and cap-
ping or lamination during tableting. For example, in a study
of the influence of the lubricant magnesium stearate on tablet-
ing indices of maltodextrins with serially increasing molecular
weight, the TS, BI, and BFI were found to decrease with in-
creasing level of magnesium stearate.16 This effect was more
pronounced with the more plastic high molecular weight mal-
todextrin (M040) that exhibited almost 10-fold lower TS and
fourfold lower BI when mixed with 0.48% magnesium stearate
compared to virgin material without magnesium stearate.16 In
a similar study on starches,17 the BFI was used to differen-
tiate the tendency of various starches to ameliorate the brit-
tle fracture of acetaminophen tablets during manufacturing.
In a study correlating physical properties of drugs with pro-
cessing behavior, a high BFI and low BI was seen with larger
particle size, suggesting a tendency to cap or laminate dur-
ing tableting.18 Moreover, higher BI and lower BFI was seen
with wet granulated material compared to dry granulation, in-
dicating a reduced potential for capping and the opportunity
to achieve acceptable tablet strength using wet granulation.18
Amidon showed that specially crystallized lots of ibuprofen ex-
hibited decreased powder flow properties with increasing BI in
addition to reduced particle size and greater sphericity, indicat-
ing that the mechanical properties of a material also influence
powder.3 The work of Wurster et al. demonstrated that estimat-
ing BI based on a linear function of composition was limited
to binary mixtures of powders deforming in similar manner
(plastic–plastic or brittle–brittle), whereas BI of blends of pow-
ders deforming in a dissimilar manner (brittle–plastic) seemed
to exhibit a nonlinear relationship.19,20 The DTI did not predict
behavior of new materials from a data set of indices of pre-
viously characterized materials using an artificial neural net-
work approach,21 indicating the complex nature of predicting
tablet properties for new materials. However, the nature of BI
as a measure of bonding efficiency was shown in the character-
ization of microcrystalline cellulose (MCC) with varying mois-
ture levels by Amidon and Houghton22 where both deformation
pressure and TS were shown to decrease significantly with the
moisture level greater than 5% as the excipient became more
plasticized by adsorbed water, resulting in a relatively constant
BI or bonding efficiency. This shows that materials with sim-
ilar bonding indices may have different TS in proportion to
their deformation hardness. It is also important to consider
the experimental conditions used to generate DTI as they may
impact the quantitative aspects and in turn, their predictive
ability. In summary, mechanical property characterization and
the development of predictive models is a complex function of
the properties determined through CTC (i.e., TS CP, solid fac-
tion) and DTI (i.e., bonding, plastic deformation, brittleness,
elasticity, viscoelasticity) methodologies. However, these mea-
surements when combined provide greater insight into the me-
chanical properties of pharmaceutical materials and enhance
our understanding of the impact of materials and processes on
pharmaceutical materials.
Hot melt extrusion (HME) and spray drying are being in-
creasingly employed to produce solid molecular dispersions
of poorly soluble drugs, resulting in improved solubility and
also to develop sustained, modified, and targeted drug delivery
systems.23–27 During HME of pharmaceutical dosage forms, a
blend of active ingredient, thermoplastic polymeric carrier, and
other processing aids, including plasticizers and antioxidants,
is heated and softened inside a screw extruder and then pres-
surized through a die into granules, cylinders, or films.24 The
intense mixing and agitation imposed by the rotating screw
cause deaggregation of suspended particles in the molten poly-
mer resulting in a more uniform dispersion.23 In spray drying,
the drug–polymer solution is atomized and dispersed into hot
gas, which causes the solvent to evaporate and leads to the gen-
eration of spherical particles.27 Plasticizers are used to soften
polymers and make them more flexible during melt extrusion.
They decrease the glass transition temperature and the melt
viscosity of a polymer by increasing the free volume between
polymer chains and reducing their movement with respect to
each other.23,28 While this improves the processing conditions
(lower temperature and lesser torque, improved stability) dur-
ing manufacturing of the extruded dosage form, it can also
influence the physical and mechanical properties of the extru-
date such as TS and elastic modulus.23,29 In drug–polymer solid
dispersions, the small molecule compounds (drugs) in a poly-
mer matrix can plasticize the polymer during HME, impact-
ing its mechanical properties such as reduced TS of extruded
films.30 Powders processed by HME are subjected not only to
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elevated processing temperatures but also to high pressure. The
reduced free volume further retards molecular mobility and
can prevent further densification during tableting,31,32 which
could adversely impact product performance such as drug dis-
solution. Crowley et al. showed that guaifenesin matrix tablets
containing binary mixtures of guaifenesin and ethyl cellulose,
prepared by HME exhibited considerably slower drug release
relative to those prepared by direct compression.33
While the improved dissolution rate of solid dispersions by
HME and spray-drying processes is desirable, the mechanical
properties of materials subject to these processes can impact
their ability to form acceptable compacts during tablet develop-
ment, often a desired end point in pharmaceutical formulation
development.
OBJECTIVES
The purpose of the current study was to determine the mechan-
ical properties of pharmaceutical excipients and their mixtures
processed in different ways, focusing primarily on HME and
spray drying. CTC profiles and DTI were employed in this study
with the objective of developing an improved understanding of
the impact of ingredient properties and processing on material
behavior. The basic material properties of deformation pres-
sure (i.e., dynamic hardness) and TS were measured at a fixed
SF, and these data were used to generate the tableting indices
BI, BFI, SI, and VI to gain greater insight into the mechanical
properties of these materials than is possible from compaction
characterization alone. The materials include a drug candidate
(API) and formulated mixtures of API and excipients.
MATERIALS AND METHODS
Hypromellose acetate succinate (HPMCAS) (AQOAT LF grade;
Shinetsu Corp., Japan), Copovidone (PVP VA64; BASF, Ger-
many), MCC (Avicel PH 101; FMC Corp., Philadelphia,
PA; Vivapur 102; JRS Pharma, Germany), Lactose (Phar-
matose 350 M; DFE Pharma, Germany), dibasic calcium phos-
phate anhydrous or DCP-A (A-TAB; Innophos, Cranbury, NJ),
croscarmellose sodium (AcDiSol; FMC Corp., Philadelphia, PA),
colloidal silica (Aerosil 200; Evonik Degussa Corp., Germany),
and magnesium stearate (Mallinkrodt Inc., St. Louis, MO) were
purchased and used without further treatment with the ex-
ceptions of colloidal silica and magnesium stearate that were
passed through a # 40 and # 30 mesh screen, respectively, prior
to use. Compound A was provided by Chemical Synthesis at
Hoffmann-La Roche Inc.
Hot Melt Extrusion
The excipients or blends were tested as received or processed in
the following ways. HME was performed as follows: Copovidone
was melt extruded in a Leistritz 18-mm twin-screw extruder at
165◦C at a maximum screw speed of 150 rpm. HPMCAS was
melt extruded in a Haake Minilab at 175◦C in a single screw
configuration at a speed of 250 rpm. A dispersion of Compound
A, referred to as dispersion HME, was prepared as follows:
Copovidone, HPMCAS and Compound A in an approximate
ratio of 0.3:0.5:0.2 were blended with 1% colloidal silica for 10
min, and the blend was extruded in a Leistritz 18-mm twin-
screw extruder at 175◦C at a screw speed of 150 rpm. A clear
glassy extrudate was obtained in all cases. The extrudate in
each trial was milled in a Fitzmill using a 0.033-in. mesh screen
at 3500 rpm or higher. A formulation designated as final blend
HME was prepared by mixing the dispersion HME with MCC,
croscarmellose sodium, colloidal silica, and crospovidone for 10
min at 22 rpm in a Turbula blender. The blend was lubricated
with magnesium stearate for 2 min.
Spray Drying
A 5% solution of HPMCAS in acetone was spray-dried (Anhy-
dro SD35; SPX Corporation, Charlotte, North Carolina) at 80–
100◦C inlet and outlet temperature of 65–75◦C. The material
collected was used without further treatment.
Preparation of Compacts
Compacts of HPMCAS, copovidone, MCC, DCP-A, and lactose
in an unprocessed (“as is”) and processed (HME, SD) state were
prepared over a range of SF (approximately 0.8–0.9). In addi-
tion, compacts of mixtures of these excipients with or with-
out Compound A were prepared. For each material, flat-face,
square compacts of 3/4-in. size and weighing approximately 4.5 g
were prepared in a triaxial press at varying CP. Compacts were
compressed and held at pressure for 90 s followed by a 120-s lin-
ear decompression profile using computer control to maintain
punch and die-wall pressure approximately equal. Compacts
were stored over night at room temperature and 40% RH prior
to testing. Compacts were evaluated for SF and subjected to
static and dynamic indentation and tensile testing as described
below. The TS was determined based on the force necessary to
cause tensile failure under transverse compression, analogous
to the measurement of tablet crushing force or hardness.
True Density Measurement
The true density of all materials (g/cm3) was determined in
duplicate by helium pycnometry (Micromeritics model 1330).
Compact Testing
The CP and TS were determined at several compact SF lev-
els using quasistatic, out-of-die, tableting indices methods as
described in earlier literature.3,4,8,10,11 A specially designed a
pendulum impact device, a quasistatic indentation tester, and
a TS tester were used to measure the mechanical properties of
compacts prepared over a SF range of 0.8–0.9. The properties
measured at each SF were CP, dynamic indentation hardness
(Hd), TS, compromised tensile strength (TSo), and quasistatic
indentation hardness (Hqs). In combination with these mea-
sured properties, the DTI of BI, BFI, SI, and VI were calcu-
lated using equations described in the literature.10 Since com-
pact mechanical properties are extremely sensitive to the state
of consolidation, it is critical to compare materials at the same
SF. A standard reference state of consolidation of SF = 0.85 is a
practical target at which to compare materials. The mechanical
property at a reference SF of 0.85 was used and reported here
for comparison and estimated by interpolation from semilog
linear regression analysis of measured mechanical property
versus SF. For DCP-A, the mechanical properties were deter-
mined by interpolation at a SF of 0.65 since the standard SF
range could not be achieved due to equipment limitations and
extrapolation to SF = 0.85 was also performed for comparison
purposes.
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RESULTS AND DISCUSSION
True Density
True density values typically range from 1.1 to 1.6 g/cm3 range
for organic crystalline materials and 2.0–2.9 g/cm3 for inorgan-
ics. The true density measurements of all the organic materi-
als ranged from 1.202 to 1.537 g/cm3. The inorganic material,
DCP-A, had a higher value of 2.83 g/cm3.
Mechanical Properties of “As Is” and Processed Excipients
The mechanical properties of the materials tested are presented
in Table 1. Several common excipients (MCC, lactose monohy-
drate, and DCP-A) are included for comparison with the excip-
ients in “as is” and processed forms of interest in this study.
HPMCAS and copovidone exhibited lower dynamic hardness,
lower CP for compact formation than the reference excipients,
and moderately high TS. In addition, HPMCAS was more elas-
tic and brittle compared to the reference excipients. In com-
parison with other grades of lactose monohydrate (not shown),
the lactose monohydrate tested in this study showed proper-
ties typical of lactose excipients but with somewhat higher TS
values than that seen for some grades. MCC exhibited, as ex-
pected, very high TS and bonding properties (consistent with its
generally accepted performance characteristics as a tableting
excipient). DCP-A behaves as a typical inorganic material. It
has a high density that requires very high CP to form a compact
of moderate strength and has low elasticity (i.e., high Reduced
modulus of Elasticity and low SI). None of the materials tested
exhibited unusually high viscoelastic behavior (VI < 10).
Compression Pressure
The CP (punch force/punch area) is the pressure necessary to
produce a densified compact defined by its SF. Desirable CP
range from 40 to 125 MPa for organic materials based on the
ability of the powder to remain as a compact with desirable
TS upon unloading as well as practical loading limits of tablet-
manufacturing tooling. In comparison, DCP-A would require a
very high CP to achieve a SF in this range and pharmaceu-
tical formulations containing this excipient are typically com-
pressed to lower SF s where an acceptable TS may be achieved.
The tabletability profile (CP vs. SF) is known to be dependent
on the process used to form compacts with compression speed
being a well-known factor.8 Therefore, a direct comparison be-
tween measured CP in this study and CP obtained under dif-
ferent compression conditions such as a rotary tablet press is
not appropriate8 since CP in this study reflects the pressure
needed to form an isotropic, defect-free compact. However, a di-
rect comparison among materials at the same SF prepared by
the process outlined earlier may be done as is the case in this
study. Among the materials tested, copovidone and HPMCAS
exhibited compression forces on the low, but acceptable, end
of the spectrum. These materials are therefore relatively soft,
suggesting lower yield strength and ease of forming compacts
at a SF of 0.85. MCC and lactose had CP in the typical range,
whereas DCP-A would require a CP > 1000 MPa (extrapola-
tion to SF = 0.85), reflecting its high hardness and difficulty
in reaching a SF of 0.85 under practical conditions of tablet
compression.
For spray-dried and melt-extruded HPMCAS, the CP needed
to achieve SF of 0.85 was 24% and 61% higher than that for
“as is” material, respectively. This indicates that spray drying T
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Figure 1. Compactibility (log TS vs. SF) curves for “as is” and processed excipients.
and melt extrusion reduced the ductility that manifested as
a higher dynamic deformation pressure (Hd) for HPMCAS. By
comparison, the CP of copovidone decreased by approximately
10% upon extrusion with no change in Hd.
Tensile Strength
TS values of common organic excipients at a SF of 0.85 have
been shown to range from a low of 0.5 MPa to a high of 11 MPa34
and a TS > 1 MPa was achieved by all the “as is” materials
tested in this study. As indicated in Table 1, lactose and MCC
exhibited the lowest and highest TS among the “as is” materials
tested whereas copovidone and HPMCAS had TS in the 2–3
MPa range, indicating that these materials form acceptable,
strong compacts.
The relationship between TS and SF is referred to as “com-
pactibility” of a material and is considered a predictor of tablet
strength, independent of tableting speed, during formulation
development. In the present study, compactibility of the materi-
als was determined from tensile testing of compacts prepared at
three different SF levels >0.8 except for DCP-A for which a SF
close to this value could not be achieved within the normal CP
range. A linear relationship of log (TS) versus SF was observed
as shown in Figure 1 and is typical for various organic and
inorganic materials including commonly used excipients such
as lactose, starch, and cellulose as seen in the literature.8,35,36
TS at a SF of 0.85 (TS0.85) was used for comparison among the
materials.
In addition, the intrinsic strength at SF = 1 (TSI) was ex-
trapolated using linear regression of log (TS) versus SF plot for
each material and presented in Table 1. MCC and lactose ex-
hibited a greater TS0.85 and TSI that suggest a relatively high
degree of deformation and bonding by either plastic and/or frac-
ture mode, whereas HPMCAS and copovidone had lower TSI.
Upon HME, they exhibited even lower TS0.85 and TSI, suggest-
ing very poor ability to deform upon compression. However,
the TS of HPMCAS increased upon spray drying as seen from
Figure 2, indicating an enhanced ability to form strong com-
pacts upon loading.
Figure 2. Tensile strength (TS ± sd) of “as is” and processed
HMPCAS and copovidone (sd, standard deviation).
For HPMCAS, an increase in pressure and particle density
caused by heating and shear stress during melt extrusion in
a screw extruder seems to have increased the strength of the
milled HME particles significantly and diminished their ability
to form strong bonds at points of contact. This suggests that,
while melt extrusion can enable the formation of solid disper-
sions, the resultant extrudate may have a reduced ability to
form strong compacts upon compression that is also reflected
in the TS0.85.
Hardness (e.g., Plasticity, Ductility)
The dynamic hardness value (Hd) is an indication of the pres-
sure required under dynamic, high-speed conditions to perma-
nently deform a material. Material hardness (permanent de-
formation, hardness) is an important component of developing
and maintaining compact strength because it allows for the for-
mation and maintenance of true areas of contact between par-
ticles. Dynamic Hd values for organic tablet excipients, some-
times referred to as ductility or plasticity, typically range from
100 to 400 MPa at a SF of 0.85.4,34 Based on this, soft or ductile
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Figure 3. Dynamic hardness (Hd ± sd) of as is” and processed
HPMCAS and copovidone.
materials may be considered to exhibit Hd in the range of 70–
100 MPa whereas nonductile, hard materials may be consid-
ered to exhibit Hd > 200 MPa. The hardness of the material
is also measured under quasistatic (slow, 10 min) indentation
conditions (Hqs). The difference in these values is a measure
of the viscoelasticity, or speed dependence of the material. The
dynamic hardness values of the excipients tested are presented
in Table 1 and were within the desirable range with the excep-
tion of HPMCAS, which behaves as a relatively soft and ductile
material. This is also reflected in the low CP necessary to com-
pact this material to a SF of 0.85. DCP-A had a high dynamic
hardness value even at a low SF of 0.65, indicating that it is a
very hard material.
The dynamic hardness of HPMCAS was significantly in-
creased upon melt extrusion, as seen from Figure 3, likely due
to the increase in material density and a possible change in the
polymeric orientation with no significant changes in the chemi-
cal composition of the polymer.37 Since hard materials are diffi-
cult to mill and compact, this aspect of impact of melt extrusion
on hardness of HMPCAS must be noted. Dynamic hardness of
copovidone remained unchanged upon melt extrusion.
Reduced Modulus (Elasticity)
The reduced modulus of elasticity (E’) is a measure of the elas-
tic property of a material. While not the same as the elastic
modulus, E, it is generally proportional to E. A relatively low
value of E’ generally reflects a rather elastic material, whereas
a large E’ reflects a material that is relatively stiff. HPMCAS
had the lowest E’ and was the most elastic of the materials
tested followed by copovidone. DCP-A had a very high E’ that
indicates it is a highly inelastic material.
Tableting Indices
Brittle Fracture Index
The BFI is a measure of the brittleness of a compact and in-
dicates the mechanism of stress relief between particle bonds
during tablet decompression. The stress relief mechanism oc-
curs either by plastic deformation or bond fracture within par-
ticles. The BFI thus reflects the sensitivity of a compact to
macroscopic flaws. The BFI is scaled to range between 0 for
nonbrittle materials to 1 for very brittle or glassy materials.
BFI values below 0.3 are generally desirable for tablet formu-
lations. A BFI > 0.5 indicates that the material is quite brittle.
Figure 4. Brittle fracture index of “as is” and coprocessed excipients.
The BFI of HPMCAS was very high as seen from Table 1, indi-
cating the brittle nature of compacts formed from this material.
In comparison, copovidone exhibited only moderately low brit-
tleness (BFI = 0.26) similar to that of lactose whereas MCC
was the least brittle.
Upon spray drying and melt extrusion, the BFI decreased
for both HPMCAS and copovidone, as shown in Figure 4. The
BFI values were 0.3–0.4 for HPMCAS SD and HME and ∼0.1
for copovidone HME. This suggests that processes such as
spray drying and melt extrusion can lower the brittleness of
materials.
Bonding Index
The BI is a measure of the survival of tablet strength following
decompression. It is therefore a measure of bonding efficiency
and characterizes the tendency of the material to remain in-
tact after tableting. It is determined under dynamic conditions
(BId) representative of high-speed compression and under qua-
sistatic (BIqs) or slow compression conditions. At maximum CP,
the bonded areas are at a maximum because the true areas
of contact are maximized. During decompression, some of that
area is “lost” due to elastic recovery, additional plastic deforma-
tion, and/or fracture. A high BI suggests that a relatively larger
proportion of the strength formed during compression remains
intact after decompression. Typical values of BId range from
0.002 for excipients that are considered to be weakly bonding
to 0.03 or greater for excipients that exhibit strong bonding abil-
ity (e.g., MCC).4,34 The BId of copovidone (0.026) and HPMCAS
(0.038) was higher than that of lactose (0.011) (Table 1), indi-
cating that during the compression–decompression process, a
large fraction of the true area of contact is maintained for these
two materials and that they are relatively efficient in their
bonding properties. MCC, given its highly plastic deformation,
had the highest BId value (0.044). In comparison, DCP-A has a
low BI, which reflects the need for a high CP to form compacts
of moderate strength. It is worth pointing out, however, that
despite the low BI of DCP-A, it is still an acceptable excipient
for tablet development since tablets with acceptable strength
can be achieved using practical CP.
The BId decreased significantly for both HPMCAS and
copovidone upon melt extrusion, as seen from Figure 5. This
suggests that the decrease in BFI upon melt extrusion of these
excipients, though desirable, did not translate into an apprecia-
ble increase in plasticity. Since BId is a ratio of TS to dynamic
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Figure 5. Dynamic bonding index of “as is” and coprocessed excipi-
ents.
hardness, a decrease in TS or increase in dynamic hardness
can lower BId. For both excipients, upon melt extrusion, the TS
decreased significantly while dynamic hardness remained the
same for copovidone but increased for HPMCAS. The decrease
in BId with melt extrusion was more significant for HPMCAS.
The practical implication of this observation is that it would
require higher CP to prepare compacts of melt-extruded HPM-
CAS with acceptable hardness and therefore formulation of
tablets containing melt-extruded HPMCAS may require use of
materials that have higher BId such as MCC or even HPMCAS
in “as is” state. As stated earlier, the process of melt extru-
sion is essentially a densification process as the materials are
subject to a high pressure resulting in a higher dynamic hard-
ness. Upon milling the extrudate, the hard particles exhibit
poor bonding and lower TS, resulting in a CP 61% greater than
for “as is” material to achieve a SF of 0.85. This is similar to the
finding on the poor compressibility of melt-extruded particles.32
Spray-dried HPMCAS had a higher BI than “as is” material.
The impact of dynamic hardness (or ductility, Hd) on CP
needed to achieve SF of 0.85 is shown in Figure 6. With an
increase in Hd, the CP to achieve SF of 0.85 was greater as
expected since the deformation properties of a material would
be expected to influence the CP needed to form a compact. A
Figure 6. Effect of Hd of excipients on CP (CP ± sd) to achieve SF of
0.85 (Inset: includes DCP-A data at SF of 0.85).
linear regression of the data in Figure 6 was performed with-
out including the DCP-A values. Using the regression equation
(r2 = 0.5531), the CP for DCP-A at Hd of 7900 MPa, repre-
senting a SF of 0.85, was predicted at 3438.2 MPa whereas
the observed CP was 3530 MPa. This indicates good agreement
between the two values, and that the relationship between Hd
and CP is quite linear given the limited data set for the ma-
terials tested. The inset in Figure 6 shows the regression line
including experimental DCP-A data.
Strain Index
The SI is a measure of the elasticity of a compact material. A
material with a high SI will likely exhibit higher elastic recov-
ery after compression. In comparing the materials tested, HPM-
CAS was found to exhibit a relatively higher SI, indicating its
greater elasticity than other materials. In addition, the SI was
higher for spray-dried and melt-extruded HPMCAS. The higher
elasticity can also lead to a lower TS of the compact, which may
further explain the lower BId for melt-extruded HPMCAS. This
is also reflected in the reduced modulus of elasticity mentioned
earlier. The SI of copovidone, lactose, and MCC was similar.
The SI of DCP-A was very low, indicating its lack of elasticity.
Viscoelasticity
A comparison of the dynamic (Hd) and quasistatic hardness
(Hqs) values can be used to assess the viscoelastic (VE) na-
ture of a material. Viscoelasticity is a kinetic phenomenon that
refers to a material’s ability to rapidly relieve stresses during
powder compression. Viscoelasticity values in the range 2–10
are noted in Table 1 are commonly observed for pharmaceuti-
cal excipients and reflect a minimal (e.g., typical) dependence of
pharmaceutical material properties on the rate of loading dur-
ing compact formation or tablet press speed.4 For some poly-
meric materials, the viscoelasticity value can approach 1000
or more (e.g., pregelatinized starch), indicating a significant
dependence of material deformation on the rate of loading (or
press speed) and time of storage effects. All the materials tested
in this study exhibited VE in the range of 2–10, suggesting
the dependence of compact strength on press speed would be
similar to excipients such as lactose and MCC. However, the
relatively higher values for melt-extruded HPMCAS suggest a
potentially greater dependence on the rate of loading or press
speed.
Mechanical Properties of Formulations of Compound A
The mechanical properties of formulations containing Com-
pound A were also evaluated. The TS of melt-extruded copovi-
done, HMCAS, dispersion HME, and final blend HME is shown
in Figure 7. The TS varied in the order of HPMCAS HME <
copovidone HME < dispersion HME < final blend HME. The in-
clusion of Compound A and copovidone in the dispersion HME
increased the TS and adding MCC to form the final blend HME
further increased the TS compared to dispersion HME alone.
The BId of dispersion HME was intermediate to that of
copovidone and HPMCAS HME, which indicates an associa-
tive mixture effect whereby addition of copovidone to HPM-
CAS increases its BId. Upon addition of plastically deforming
MCC to the dispersion HME, the BId of final blend HME in-
creases, reaching a value of 0.008, similar to that of copovidone,
as shown in Figure 8.
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Figure 7. Tensile strength (TS ± sd) of melt extruded excipients and
their mixtures with Compound A.
Figure 8. Dynamic bonding index of melt extruded excipients and
their mixtures with Compound A.
In the present study, it was observed that when materials
with different deformation behaviors are mixed in different ra-
tios, the resultant mixtures exhibited a composite deformation
behavior that was intermediate to that of the individual compo-
nents. These results demonstrate the ability of the compaction
Figure 10. Britle fracture index of melt-extruded excipients and their
mixtures with Compound A.
data and tableting indices to quantitate the impact of API and
excipients on intermediate and final product properties.
The impact of the addition of HPMCAS to copovidone dur-
ing melt extrusion on the TS of tablets prepared from milled
extrudate is shown in Figure 9. It is seen that with increas-
ing amount of HPMCAS up to 80%, the tablet TS is reduced
up to three- to fourfold over a compression force range of 12–
33 kN. These data are also consistent with the conclusion that
the properties of mixtures exhibit a composite behavior that
is intermediate and roughly additive in proportion to their re-
spective volume fractions, to that of the individual components.
The addition of plastically deforming materials such as MCC is
therefore effective in compensating for the BId lowering effect
of HPMCAS and predictable based on the results of Figure 9.
The BFI for formulations of Compound A is shown in
Figure 10. The high BFI of HPMCAS HME extrudate in its
glassy state suggests a lack of significant bonding contacts
among the particles resulting in low TS of compacts. The lower-
ing of BFI upon addition of copovidone and MCC is likely due to
the resultant significant plastic deformation of these excipients
leading to a higher compact TS and reduced brittleness.
Figure 9. Tensile strength of tablets composed of mixtures of milled extrudate of HPMCAS and copovidone.
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SUMMARY AND CONCLUSIONS
The compaction properties (compactability, tabletability, com-
pressibility) and Hiestand DTI were determined for a wide
range of individual excipients in an “as is” and processed states.
Furthermore, mixtures of excipients with and without an exper-
imental drug Compound A in various states of processing begin-
ning from melt extrusion to a final “compression ready” blend
were prepared and evaluated for tableting indices. The over-
all analysis shows that the compaction properties and tablet-
ing indices can be effectively used to delineate and quantitate
compression behavior of the excipients and differentiate the
changes in their deformation behavior from “as is” to processed
state. Importantly, the compaction properties and tableting in-
dices of the materials tested indicate a composite behavior for
mixtures containing excipients of different deformation that
reflects the properties of the individual materials within the
composite material. The bonding indices of poorly deforming
materials were improved when plastically deforming materials
were added, and this was supported by tableting studies. The
DTI together with compaction properties (CP, SF, TS) thus pro-
vide an important and insightful “window” into the deformation
attributes of different types of excipients. The changes in these
attributes that occur as a result of processing can be quanti-
tated, thus enabling the selection of excipients to compensate
for material deficiencies during tablet development and develop
formulations that can yield an acceptable tablet during powder
compression.
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